CN117940450A - 抗csp抗体 - Google Patents

抗csp抗体 Download PDF

Info

Publication number
CN117940450A
CN117940450A CN202280053427.0A CN202280053427A CN117940450A CN 117940450 A CN117940450 A CN 117940450A CN 202280053427 A CN202280053427 A CN 202280053427A CN 117940450 A CN117940450 A CN 117940450A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
sequence shown
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280053427.0A
Other languages
English (en)
Chinese (zh)
Inventor
D·E·艾默灵
R·R·凯彻姆
S·M·利鲍
W·沃克穆斯
K·L·威廉姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azika Co
Original Assignee
Azika Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azika Co filed Critical Azika Co
Publication of CN117940450A publication Critical patent/CN117940450A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C07K16/205—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280053427.0A 2021-06-17 2022-06-16 抗csp抗体 Pending CN117940450A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211820P 2021-06-17 2021-06-17
US63/211,820 2021-06-17
PCT/US2022/033877 WO2022266383A1 (en) 2021-06-17 2022-06-16 Anti-csp antibodies

Publications (1)

Publication Number Publication Date
CN117940450A true CN117940450A (zh) 2024-04-26

Family

ID=84526612

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280053427.0A Pending CN117940450A (zh) 2021-06-17 2022-06-16 抗csp抗体

Country Status (9)

Country Link
US (2) US11655290B2 (enExample)
EP (1) EP4355774A4 (enExample)
JP (1) JP2024524895A (enExample)
KR (1) KR20240047964A (enExample)
CN (1) CN117940450A (enExample)
AU (2) AU2022292722B2 (enExample)
IL (1) IL309422A (enExample)
MX (1) MX2023014984A (enExample)
WO (1) WO2022266383A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024214379A1 (en) * 2023-02-03 2025-08-21 Atreca, Inc. Anti-csp antibody variants
WO2025194069A1 (en) * 2024-03-15 2025-09-18 Atreca, Inc. Anti-csp antibody variants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2927892A (en) 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CN103732738A (zh) * 2011-04-28 2014-04-16 小利兰斯坦福大学托管委员会 与样品相关的多核苷酸的鉴定
TW201708260A (zh) 2015-07-22 2017-03-01 優瑞卡醫療公司 靶向ｐｓａ胜肽／ｍｈｃ複合體之構築體及其用途
US11066464B2 (en) * 2016-03-21 2021-07-20 Kymab Limited Anti-malarial antibodies that bind circumsporozoite protein
US20220195023A1 (en) 2019-02-19 2022-06-23 Atreca, Inc. Anti-csp antibody variants

Also Published As

Publication number Publication date
EP4355774A4 (en) 2025-05-07
JP2024524895A (ja) 2024-07-09
US20230167169A1 (en) 2023-06-01
NZ806561A (en) 2025-06-27
US11655290B2 (en) 2023-05-23
KR20240047964A (ko) 2024-04-12
IL309422A (en) 2024-02-01
US20230002483A1 (en) 2023-01-05
WO2022266383A1 (en) 2022-12-22
MX2023014984A (es) 2024-03-12
AU2025220692A1 (en) 2025-09-11
AU2022292722A1 (en) 2024-01-04
US12545723B2 (en) 2026-02-10
EP4355774A1 (en) 2024-04-24
AU2022292722B2 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
KR102414120B1 (ko) 인터류킨-21 뮤테인 및 치료 방법
DK2740744T3 (da) Sp35-antistoffer og anvendelser deraf
KR101251157B1 (ko) Ｃｄ37-특이적 결합 분자 및 ｃｄ20-특이적 결합 분자를사용한 ｂ-세포 감소
CN107207588B (zh) 针对tau的抗体和其用途
US8546539B2 (en) Fc receptor-binding polypeptides with modified effector functions
JP7507160B2 (ja) ヒトｔｒｂｖ９に特異的に結合するモノクローナル抗体
KR20230017841A (ko) Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도
TW202304992A (zh) 用於免疫效應細胞重導向的材料及方法
US20240076386A1 (en) Anti-e-selectin antibodies, compositions and methods of use
CN117940450A (zh) 抗csp抗体
CN116323668A (zh) 治疗性抗体及其用途
CN114174536B (zh) 抗trem-1抗体及其用途
CN114144435B (zh) 针对人trem-1的抗体及其用途
CN101896502B (zh) 抗人TNFα单抗、分子进化及其应用
CN117412992A (zh) 靶向cd47和pd-l1的双特异性抗体及其使用方法
KR102705172B1 (ko) 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도
JP7691977B2 (ja) 抗ｔｉｒｃ７抗原結合タンパク質
CN117396511A (zh) 靶向cd47和pd-l1的双特异性抗体及其使用方法
WO2025194069A1 (en) Anti-csp antibody variants
HK40095327A (zh) 含有突变轻链可变区骨架的单链抗体片段
HK40089733A (zh) 治疗性抗体及其用途
EA047127B1 (ru) Конъюгаты, содержащие мутеины интерлейкина-21, и способы лечения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination